May 14, 2020
Regulus Therapeutics Reports First Quarter 2020 Financial Results and Recent Updates
Apr 30, 2020
US Societal Economic Burden of an Inherited Kidney Disease Estimated at $7-10 Billion
Mar 12, 2020
Regulus Reports Fourth Quarter and Year-End 2019 Financial Results and Recent Updates
Oct 16, 2019
Regulus Therapeutics Presents Preclinical Data Identifying RGLS4326 as a Potential Disease-Modifying Treatment for Autosomal Dominant Polycystic Kidney Disease at OTS Annual Meeting
Oct 15, 2019
Study Demonstrates Continuing Education Improved Health Care Providers' Knowledge of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Sep 12, 2019
Regulus Therapeutics Announces Publication in Nature Communications Identifying RGLS4326 as a Potential Promising Treatment for ADPKD
Jul 23, 2019
Regulus Therapeutics Announces RGLS4326 Program Update
May 06, 2019
Regulus Therapeutics Announces Restructuring of Term Loan
Jan 31, 2019
2018 Pipeline Review on Renal Diseases - Which Companies are the Most Active within Each Pipeline
Oct 26, 2018
Research in Polycystic Kidney Disease Takes an Important Step Forward
Oct 22, 2018
Regulus to Present Preclinical Data Supporting RGLS4326 as a Novel Therapeutic in Development for Autosomal Dominant Polycystic Kidney Disease at ASN's Kidney Week 2018
May 10, 2018
PANTHERx® Specialty Pharmacy Selected by Otsuka to Distribute JYNARQUE
May 01, 2018
Regulus Initiates Multiple Ascending Dose Study in Healthy Volunteers of RGLS4326 for the Treatment of ADPKD
Apr 27, 2018
Avella Selected by Otsuka to distribute JYNARQUE
Apr 24, 2018
JYNARQUE(TM) Approved as First Treatment for Polycystic Kidney Disease
Dec 19, 2017
Regulus Announces First-in-Human Dosing for Phase I Study of RGLS4326 for the Treatment of Autosomal Dominant Polycystic Kidney Disease